RxDoctor Payments Data

Gretchen Fowell

Family · Great Falls, MTNPI 1649209867

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.2% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $534, 6.9 times the $77 reported in 2021.

$1,748in general payments, 2019–2025

Across 92 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Organon$170
  • Astellas Pharma US Inc$118
  • Sage Therapeutics, LLC$104
  • Daiichi Sankyo Inc.$50
  • Pfizer$20
  • plus $110 from 7 others
$1,819in research payments, 2019–2025

Across 10 payments — averaging $181.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Food & beverage$1,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,748 in reported general payments places this provider in the 85th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$12,472
Medicare patients
71
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$15,229
OzempicSemaglutide13$12,284
Aripiprazole20$1,266
Levothyroxine Sodium99$766
Potassium Chloride22$337
Meloxicam43$297
Losartan Potassium42$275
Bupropion XlBupropion Hcl24$274
Sertraline Hcl26$266
Atorvastatin Calcium49$252
Lisinopril70$244
Omeprazole38$240
Simvastatin46$195
Metformin Hcl25$149
Lorazepam30$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$15,22914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 481 family providers in Montana.

Other family in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →